What Duphaston Treats: Main Uses and Benefits

Duphaston (dydrogesterone) is commonly used when short-term symptomatic assistance is needed across several key areas of women's reproductive health, particularly in situations involving certain distressing symptoms linked to functional hormonal changes. It is commonly used across conditions presenting with acute episodes and relevant when supportive symptom management is appropriate. The medication is indicated for use in these therapeutic domains. It helps address symptom clusters that may become intense or disruptive.

The medication is used in situations involving certain distressing symptoms across conditions characterized by periods of heightened symptoms, including those related to miscarriage risk, painful menstruation (dysmenorrhea), endometriosis, and Premenstrual Syndrome (PMS). It supports the patient during difficult episodes by easing distress and contributes to improved day-to-day comfort during symptomatic periods. It is applied in scenarios where additional management of discomfort is required, including supportive management for symptoms linked to luteal insufficiency. This involves using the medication when symptoms become more noticeable.

Quick Fact: Supportive Relief for Challenging Symptoms

Regulatory References

1. NAFDAC Product Information for Duphaston 10 mg

Eligibility Profile: Who Can and Cannot Use Duphaston

The eligibility for Duphaston (dydrogesterone) is strictly defined by regulatory labeling, which outlines the populations permitted to use the medicine and those who must be excluded or restricted.

Eligibility also prohibits use in patients with a known hypersensitivity to the drug or excipients, including rare hereditary conditions like galactose intolerance. In cases where dydrogesterone is used in combination with an estrogen, the absolute contraindications for the estrogen also apply.

The effectiveness of Duphaston (dydrogesterone) may be reduced when used concurrently with other medicines that increase the rate at which the body metabolizes, or breaks down, steroid hormones. This effect, known as enzyme induction, leads to lower levels of dydrogesterone in the bloodstream, potentially lessening its therapeutic effect.

Patients should inform their healthcare provider about all prescription and non-prescription drugs, as well as any herbal remedies or supplements they are taking.

Known Drug Interactions

Herbal and Other Interactions

Certain herbal products are also known to induce these metabolic enzymes and should be discussed with a doctor, especially when starting treatment with Duphaston. This includes preparations containing St. John's Wort (Hypericum perforatum).

When dydrogesterone is used in Hormone Replacement Therapy (HRT) in combination with estrogens, the standard precautions and contraindications associated with estrogen use must also be strictly followed. The concomitant use of ritonavir or nelfinavir, typically HIV medications, may also induce metabolic enzymes, affecting dydrogesterone levels. Dose adjustments or alternative treatments may be necessary in the case of a known interaction.

Duphaston (dydrogesterone) functions as a selective progesterone receptor (PR) agonist. Following systemic absorption, the molecule binds with high affinity to the PR within target cells, primarily in the endometrium. It is characterized by high specificity, exhibiting no measurable affinity for androgen, estrogen, glucocorticoid, or mineralocorticoid receptors, thereby avoiding off-target steroid pathway modulation. Activation of the PR initiates a cascade that modulates gene transcription, leading to the regulation of endometrial cell proliferation and differentiation. The primary intracellular consequence is the transformation of the proliferative endometrium into a full secretory state. This physiological modulation involves the induction of specific protein synthesis necessary for secretory maturation, which stabilizes the endometrial tissue. The resulting system-level consequence is the complete morphological and functional development of the secretory endometrium.

How Duphaston (Dydrogesterone) is Used: Official Administration Guidelines

Duphaston is strictly administered via the oral route as a 10 mg film-coated tablet, following specific schedules. The structure of its usage is highly dependent on a cyclic or sustained daily pattern, as detailed in official prescribing information.

Administration Details and Procedural Rules

Time-Bound Regimens and Special Conditions

Treatment regimens are defined by specific time boundaries. For regulating the menstrual cycle or addressing luteal insufficiency, usage is limited to specific cycle days (e.g., Day 11 through Day 25). In cases of threatened or habitual miscarriage, the treatment is typically sustained but limited to a defined gestational period, often up to the 20th week of pregnancy.

If a dose is missed, the standard procedure is to skip the forgotten dose and continue with the next scheduled dose at the regular time; a double dose must not be taken to compensate. Use in adolescents before menarche has no established standard dosage and is considered outside the relevant use context.

Research evidence / Overview of Studies for Duphaston

This overview is a patient-friendly summary of the types of research and reported findings concerning Dydrogesterone (Duphaston). It focuses on the structure of clinical evidence, adhering strictly to official and peer-reviewed sources, and does not offer any clinical advice, treatment instructions, or claims of efficacy.

Evidence for Use in Threatened Miscarriage

The evidence base for Dydrogesterone in cases of threatened miscarriage includes Randomized Controlled Trials (RCTs) and comprehensive systematic reviews that combine and analyze results from multiple trials. This research was conducted during periods of increased symptom activity in pregnant women, specifically those in the first trimester (usually 5 to 12 weeks) who were experiencing active vaginal bleeding.

Findings describe patterns observed in the studies when comparing dydrogesterone to placebo or standard expectant management. Some trials described a pattern in which measurements of the continuing pregnancy rate measured were observed to be different in the dydrogesterone group compared to the control group. However, findings were mixed across various individual RCTs, with some reporting no statistically significant difference in the live birth rates compared to control groups. These variations sometimes stem from differences in the study design or the patient populations examined.

Outcomes Studied for Threatened Miscarriage

The clinical trials for this indication focused on monitoring clear, functional measures rather than subjective assessments. The studies were concerned with outcomes related to systemic or functional imbalance during early pregnancy. The core axes of investigation included the monitoring of miscarriage rate, the eventual delivery status, and the evaluation of immunological or hormonal factors that studies were exploring.

Evidence for Use in Recurrent Miscarriage

The research landscape for Dydrogesterone includes extensive analysis of Recurrent Miscarriage (also known as habitual abortion). The evidence comes primarily from numerous meta-analyses that pool data from controlled trials and observational studies. These studies explored whether the use of Dydrogesterone was related to measurements of subsequent pregnancy loss in women who had already experienced two or more consecutive miscarriages.

Data show patterns related to live birth rates measured in the study differed in the dydrogesterone-treated groups compared to control groups in women identified with this specific condition.

Focus on Idiopathic Recurrent Miscarriage

The research base primarily focuses on the subgroup of women whose recurrent miscarriage is classified as idiopathic, meaning the cause of the pregnancy loss remains unexplained after standard medical investigation. The results apply only to the populations studied, which means the data focuses on this particular subgroup, and data for cases with known genetic or structural causes of loss remain less characterized in the high-level evidence synthesis.

Key Studies & References

1. The efficacy and safety of dydrogesterone for treatment of dysmenorrhea: An open-label multicenter clinical study
2. Dydrogesterone as an Option in the Medical Treatment of Endometriosis: A Brief Comment

Common questions about Duphaston (FAQ)

Q: Why is Duphaston sometimes given for menstrual problems?

Official documents describe Duphaston as being used to address deficiencies of the hormone progesterone that are associated with menstrual disorders, such as painful or irregular periods. The medicine is intended to regulate the growth and shedding of the womb lining, which supports the physiological processes involved in the menstrual cycle.

Q: Is it normal to have some spotting while taking Duphaston?

According to the official patient information documents, unexpected vaginal bleeding or spotting may occur while using this medicine. This is noted as a possibility, particularly during the initial months of treatment.

Q: Can Duphaston change the results of blood tests?

Official pharmacological data indicates that dydrogesterone, the active ingredient, does not interfere with a specific type of test used to analyze natural progesterone production, which is based on the excretion of pregnanediol.

Q: How quickly does Duphaston start to work in the body?

Pharmacokinetic studies, which track how the medicine moves through the body, show that dydrogesterone is rapidly absorbed. Peak concentrations are typically reached within 0.5 to 2.5 hours after taking a tablet, and consistent (steady-state) concentrations are usually reached within 3 days of starting treatment.

Q: What is the typical length of time a patient might use Duphaston?

The required duration of use is not fixed and is highly dependent on the condition being treated. Regulatory guidance outlines regimens that range from use over specific cycle days for fertility concerns, for at least three consecutive cycles in some cases of infertility, or up to the 20th week of pregnancy for habitual miscarriage.

Q: How long has dydrogesterone been available on the market?

Regulatory records indicate that the innovator product containing dydrogesterone has a long history of use, having been registered in some countries as early as 1968.

Q: Is Duphaston known to cause fatigue or sleepiness?

Official safety information lists both dizziness and drowsiness (somnolence) as possible side effects that have been reported with this medicine.

Q: Will Duphaston interfere with my ability to drive or operate machinery?

Official warnings state that caution is noted for situations like driving or operating machinery if a patient experiences side effects such as dizziness or drowsiness.

Q: How does Duphaston relate to IVF or assisted conception treatments?

Dydrogesterone is officially indicated for use as luteal phase support (LPS) as part of an Assisted Reproductive Technology (ART) procedure, such as in vitro fertilization (IVF).

Q: Is Duphaston used to help support a pregnancy?

Official indications for use during pregnancy are specific and include the treatment of habitual (recurrent) miscarriage and threatened miscarriage, both of which are specific conditions for which hormonal support is indicated.

Q: What is the difference between Duphaston and natural progesterone?

Dydrogesterone is a synthetic substance known as a retroprogesterone. Although it is structurally similar to the body’s natural progesterone, it is characterized by high selectivity for the progesterone receptor and does not exhibit other effects, such as androgenic or estrogenic properties.

Q: How long after stopping Duphaston does bleeding usually start?

In treatment regimens designed to regulate cycles, such as for dysfunctional uterine bleeding, withdrawal bleeding is generally described as occurring a few days after the final tablet has been taken.

Q: Are weight changes a possible side effect of Duphaston?

Yes, official safety documents list weight gain as a possible side effect of this medicine.

Q: Are there any herbal supplements that could interact with Duphaston?

The official interaction documents highlight that preparations containing the herb St. John's Wort (Hypericum perforatum) may decrease the effectiveness of dydrogesterone due to enzyme induction. Official documents advise that all herbal use be discussed with a healthcare provider.

Q: Is it necessary to avoid alcohol completely while using Duphaston?

Official patient information indicates there are no known direct interactions between dydrogesterone and alcohol. However, it is generally recommended that caution regarding alcohol consumption be discussed with a healthcare professional.

Q: Are there restrictions on foods or drinks when taking this medicine?

Official instructions note that Duphaston can be taken either with or without food.

Q: Can Duphaston be used by women who have gone through menopause?

Yes, Duphaston is officially indicated for use in Hormone Replacement Therapy (HRT). It is used to counteract the effects of unopposed estrogen on the endometrium (womb lining) in women who have an intact uterus and are experiencing disorders due to menopause.

Q: Does Duphaston affect fertility or ovulation after the treatment course is finished?

Official pharmacological descriptions note that while the medicine is being used, dydrogesterone does not inhibit or interfere with the process of ovulation.

Q: What is the purpose of taking Duphaston for only part of the menstrual cycle?

The prescribed cyclic administration pattern is described as being necessary to achieve a full secretory transformation of the endometrium (womb lining). This pattern is intended to support the management of the risk of the abnormal thickening of the lining that can occur when the body has too much estrogen relative to progesterone.

Q: Is it true that Duphaston is approved for use in certain countries but not others?

Yes, regulatory information confirms that the medicine’s approval status varies by location. Dydrogesterone is approved and available in many regions governed by bodies like the EMA, but it is not currently approved for marketing by the U.S. FDA.

Q: Can Duphaston be used during breastfeeding?

Official documents state that use is generally not recommended while breastfeeding. This is because it is not known whether dydrogesterone passes into breast milk, as there is an unknown potential risk to the breastfed child.

Q: Does Duphaston contain lactose or other common allergens?

The full list of inactive ingredients (excipients) used in the tablet, which may include substances like lactose, is detailed in the official prescribing information. The official documentation indicates that patients with known allergies or conditions like galactose intolerance should consult this list.

Q: Can Duphaston affect your blood pressure?

Official cautionary statements mention that this medicine should be used with care in patients who have conditions that may worsen with fluid retention, such as high blood pressure (hypertension).

Q: Is Duphaston safe for teenagers to use?

Official safety data states that use in children and adolescents under 18 years of age is restricted because safety and efficacy in this age group have not been formally established.

Q: What happens if I accidentally take more than the prescribed amount?

Regulatory documents covering overdose state that there are no specific antidotes known for dydrogesterone overdose. Therefore, any resulting medical treatment is described as being symptomatic.

Q: Does Duphaston help regulate hormone balance?

Official patient information describes the core function of the medicine as compensating for and helping to restore the balance of hormones in the body when there is insufficient production of natural progesterone.

Q: What scientific studies support the use of Duphaston for uterine bleeding?

Official indications for use confirm that dydrogesterone is approved for the management of abnormal uterine bleeding, specifically when the cause is related to hormonal imbalance and not another underlying organic pathology.

How to Store and Dispose of Duphaston

Duphaston (dydrogesterone) tablets must be stored according to specific regulatory requirements to maintain product stability and safety. The product must be stored at a temperature not exceeding 30 C and it must not be frozen. To ensure product integrity, the medicine must be kept in the original package and out of the sight and reach of children.

All unused or expired Duphaston must be handled in accordance with official disposal instructions. It is required to dispose of the product in accordance with local regulations, and the medicine should not be thrown into household waste or wastewater. The tablets must also not be used after the expiry date shown on the packaging.